FDA Clocks Review Time for LOQTORZI Patent Boost
Published Date: 5/30/2025
Notice
Summary
The FDA has set the official review period for LOQTORZI, a new medicine, so its patent can be extended. This helps the company behind LOQTORZI get extra time to protect their invention before others can copy it. This means the drug maker could have more exclusive sales time, which might impact when generic versions can appear.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Patent Extension May Delay Generics
The FDA set the official regulatory review period for LOQTORZI so the drugmaker can apply to extend a patent on this human biological product. That extension could give the company extra exclusive sales time for LOQTORZI and might delay when generic or biosimilar versions can appear. If you buy or pay for LOQTORZI, that could mean waiting longer for cheaper alternatives.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-09637 — Constellation Energy Generation, LLC; Peach Bottom Atomic Power Station Units 2 and 3; Draft Supplement to Environmental Impact Statement
The NRC is asking for public feedback on extending the Peach Bottom Atomic Power Station’s license to keep running Units 2 and 3 for 20 more years. This affects people near Peach Bottom Township, PA, and looks at environmental impacts and possible alternatives. The process includes chances to speak up and could influence energy plans and local safety for decades.
Next: 2025-09756 — Holtec Decommissioning International, LLC and Holtec Palisades, LLC; Palisades Nuclear Plant; Environmental Assessment and Finding of No Significant Impact
The Palisades Nuclear Plant is getting a green light to keep running and refuel, thanks to Holtec and some federal support. This means the plant can keep providing power safely without big environmental worries. The government’s loan guarantee helps make sure the plant stays up and running smoothly and on time.